Gibco™ Hybridoma SFM is a serum-free, very low-protein medium specifically developed for the ability to support the growth of hybridomas for antibody production. Gibco™ Hybridoma SFM features:
• Ability to support suspension and stationary hybridomas and myelomas
• Complete, ready-to-use formulation
• Serum-free, very low-protein formulation

Ability to support suspension and stationary hybridomas and myelomas
Suitable for the culture of recombinant myeloma lines as well as traditional hybridomas, Gibco™ Hybridoma SFM provides high cell densities and IgG production. Cholesterol-dependent cultures such as NS0 require the addition of 250x Cholesterol Lipid Concentrate.

Complete, ready-to-use formulation
Once reconstituted, Gibco™ Hybridoma SFM, powder is a complete medium that is ready-to-use. No supplementation is required.

Serum-free, very low-protein formulation
Gibco™ Hybridoma SFM is a serum-free, very low-protein formulation, allowing for easier purification of your protein of interest. Gibco™ Hybridoma SFM contains < 20 μg/ml total protein.

Product Use
For Research Use Only. Not for use in diagnostic procedures. Customers using Gibco™ Hybridoma SFM in a manufacturing process, who have a submission with the FDA, may request a letter of authorization from us to reference our Type II Drug Master File (DMF).

cGMP Manufacturing and Quality System
Gibco™ Hybridoma SFM is manufactured at a cGMP compliant facility located in Grand Island, New York. The facility is registered with the FDA as a medical device manufacturer and is certified to ISO 13485 standards.